The infiltration of LF9-specific CD8+ T cells into the TME strongly suggested the immunogenicity of LF9 eliciting spontaneous host immune responses in vivo, supporting its role as a tumor-associated antigen in the clinical setting. This evidence concerns the gene CD8A and neoplasm.